# Aurobindo Pharma Ltd (AUROPHARMA)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1454.6
Day Change: -0.61%
52W High: ₹1528.35
52W Low: ₹994.35
Market Cap: ₹87,910 Cr

## Valuation
P/E: 25.66
P/B: 2.5
EPS: ₹58.89
Book Value: ₹603.39
Dividend Yield: 0%

## Returns
1Y Return: 19.71%

## Profitability
ROE: 0%
ROCE: 15.31%
Debt/Equity: 0.22
Revenue Growth: 8.4%
Profit Growth: 7.6%
EBITDA Margin: 20.15%
Operating Margin: 15.14%

## About
Aurobindo Pharma Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Aurobindo Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
- Announcement: Curateq Biologics Receives CDSCO Marketing Authorisation (Form CT 23) For Bevqolva® (Bevacizumab Biosimilar)
- BSE Filing: Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-25T20:00:13.927Z
Price History Updated: 2026-05-25T05:24:24.330Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:24:24.330Z
Quant Updated: 2026-05-25T05:24:24.330Z
Sentiment Updated: 2026-05-25T05:24:24.330Z
Financials Status: current
Financials Updated: 2026-05-18T02:53:40.359Z
Financials Last Attempt: 2026-05-18T02:53:40.359Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹8089 Cr
Operating Profit: ₹2137 Cr (OPM 26%)
Net Profit: ₹1169 Cr
Tax: ₹1533 Cr

## Annual P&L History
Mar 2015: Rev ₹8089Cr | PAT ₹1169Cr | OPM 26%
Mar 2016: Rev ₹12103Cr | PAT ₹1571Cr | OPM 21%
Mar 2017: Rev ₹13772Cr | PAT ₹2024Cr | OPM 23%

## Balance Sheet (Mar 2015)
Total Assets: ₹9490 Cr
Total Liabilities: ₹9490 Cr
Borrowings: ₹3769 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Kambam Nithyananda Reddy, Vice Chairman & MD
- Mettu Madan Mohan Reddy, Whole-Time Director
- Makkapati  Satakarni B.E., M.B.A., Ph.D., President of Biologics, CEO of Biologics, Vaccines and Peptid & Director
- Santhanam  Subramanian, Chief Financial Officer
- Mula Surya Narayana Murthy, Senior Vice President of Accounts

---
Source: rupiya.io/stocks/auropharma
Disclaimer: For research and education only. Not investment advice.